3630 results for «979»
3630 results
Bailout techniques for complications during primary PCI
21 May 2026 – From EuroPCR 2026
This session addresses bailout techniques during primary PCI complications. It covers a range of challenging scenarios such as coronary perforations and complex procedural issues, emphasizing rapid decision-making and effective treatment strategies to improve patient outcomes in high-stakes situations.
CTO ADVANCED Level III: LIVE Educational Cases from Institut Cardiovasculaire Paris Sud, France & University Hospital Basel, Switzerland
21 May 2026 – From EuroPCR 2026
This advanced educational session features live complex chronic total occlusion (CTO) PCI cases from Institut Cardiovasculaire Paris Sud and University Hospital Basel. It emphasizes optimizing strategy selection, procedural efficiency across diverse CTO anatomies, and integrating advanced techniques into routine complex practice.
Beyond the diagnosis: a qualitative exploration of women’s experiences with cardiovascular disease
21 May 2026 – From EuroPCR 2026
This session presents a qualitative exploration of women's experiences with cardiovascular disease, highlighting unique challenges throughout their care pathway from diagnosis to rehabilitation. It shares robust patient experience data and offers recommendations aimed at improving cardiovascular care tailored to women’s specific needs.
Beyond first implant: valve-in-valve, redo and leaflet modification
20 May 2026 – From EuroPCR 2026
This session explores advanced transcatheter aortic valve therapies beyond the first implant, focusing on valve-in-valve, redo procedures, and leaflet modification techniques. Topics include bioprosthetic valve fracture, long-term outcomes from the DURA-ViV registry, simplified workflows for leaflet modification in redo-TAVI, and intravascular ultrasound evaluation of valve expansion...
The impact of calcified and resistant lesions in clinical outcome of PCI
21 May 2026 – From EuroPCR 2026
Delve into the clinical implications of calcified and resistant coronary lesions on percutaneous coronary intervention (PCI) outcomes. This session presents key registry data and study results on intravascular lithotripsy and plaque modification techniques, highlighting their impact on patient prognosis and stent performance.
New evidence for pharmacology for coronary artery disease
19 May 2026 – From EuroPCR 2026
This session presents the latest evidence in pharmacological management of coronary artery disease, featuring pivotal trials such as VESALIUS-CV and TARGET FIRST. It covers topics including evolocumab efficacy post-stenting, early aspirin cessation strategies, aspirin-free protocols after complex PCI in ACS, and comparative outcomes of clopidogrel versus...
Best complications on calcified lesions
20 May 2026 – From EuroPCR 2026
Highlighting challenging cases in calcified coronary lesions, this session presents a series of complications including stuck wires, the Kokeshi phenomenon, and multiple complications within a single vessel. It provides practical insights into rescue techniques and navigating complex procedural challenges.
TAVI complications - Prediction, reduction, avoidance
21 May 2026 – From EuroPCR 2026
This session examines prediction, reduction, and avoidance of complications associated with TAVI procedures. It covers outcomes of second-valve implantation as a bail-out for valve migration, predictors of permanent pacemaker implantation post-TAVI from the LANDMARK trial, neurological event prognostics based on timing, and management of periprocedural cardiac...
BRIGHT-4 – Bivalirudin plus a high-dose infusion versus heparin monotherapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomised trial
07 Nov 2022
Nicola Ryan provides her take on the BRIGHT-4 study, which was presented during AHA 2022 in Chicago, & simultaneously published in the Lancet.
This study was a randomised control trial designed to assess if bivalirudin plus a high dose infusion for 2-4 hours post PPCI was superior to unfractionated...
Author
BIOFLOW DAPT - Biodegradable-polymer or durable-polymer stents in patients at high bleeding risk: A randomized, open-label clinical trial
26 Aug 2023
Nicola Ryan reports on the BIOFLOW DAPT trial results presented during the ESC 2023 Congress in Amsterdam by Marco Valgimigli and published in Circulation.
BIOFLOW-DAPT is an open-label randomised trial comparing the safety and efficacy of a biodegradable-polymer sirolimus-eluting stent with a durable-polymer zotarolimus-eluting stent in high-bleeding risk patients...
Author
